Arcellx
Intelligent and adaptive cell therapies to treat the complexity of human disease.
Launch date
Employees
Market cap
CAD5.5b
Enterprise valuation
CAD4.9b (Public information from Sep 2024)
Share price
$85.43 ACLX
Gaithersburg Maryland (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 110m | 134m | 117m | 140m |
| % growth | - | - | - | - | 21 % | (12 %) | 19 % |
| EBITDA | (31.5m) | (65.0m) | (187m) | (64.1m) | (106m) | (89.7m) | (144m) |
| % EBITDA margin | - | - | - | (58 %) | (79 %) | (76 %) | (102 %) |
| Profit | (32.1m) | (65.0m) | (189m) | (70.7m) | (81.6m) | (124m) | (158m) |
| % profit margin | - | - | - | (64 %) | (61 %) | (105 %) | (113 %) |
| EV / revenue | - | - | - | 19.8x | 23.1x | 26.8x | 20.9x |
| EV / EBITDA | - | - | -5.9x | -34.0x | -29.1x | -35.0x | -20.3x |
| R&D budget | 25.1m | 46.9m | 150m | 134m | - | - | - |
| R&D % of revenue | - | - | - | 121 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Series A | ||
$85.0m | Series B | ||
| $115m | Series C | |
* | N/A | $129m | IPO |
* | $100m | Post IPO Equity | |
* | $200m | Post IPO Equity | |
| Total Funding | CAD273m | ||
Related Content
Recent News about Arcellx
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.